ResMed Inc.

The forensic screens point in a generally favorable direction, but each is a screening tool rather than a verdict. The Beneish M-Score is -2.615, below -1.78, and is labeled not in the elevated zone; that means the score did not flag a manipulation pattern, though it does not rule out problems. The Altman Z″-Score of 8.65 is in the safe zone. The Piotroski F-Score is 9 of 9 computable signals, meaning all nine computable tests passed. The operating cash flow to net income ratio of 1.25 means cash generated from operations ($1.75 billion) exceeded reported net income ($1.4 billion) in fiscal 2025. Net income rose from $1.02 billion in fiscal 2024, and equity grew from $4.86 billion to $5.97 billion. Debt is more modest: long-term debt was $658.4 million at June 30, 2025, down from $697.3 million a year earlier. The 10-Q shows $165.0 million outstanding under its Revolving Credit Agreement and Term Credit Agreement at variable rates, against cash and cash equivalents of $1,660.5 million at March 31, 2026. The company states a hypothetical 10% change in interest rates would not have a material impact on pretax income, and it has no interest rate hedging agreements. The currency side asks the most of a careful reader: swap notionals grew sharply while non-designated hedges declined slightly to $1,318.8 million from $1,410.2 million. Readers may want to look at how that hedging growth relates to the purchase obligations and to the complete tariff and supply-chain discussion.

Catalyst.According to the fiscal 2025 annual figures, revenue reached $5.15 billion, up 9.8% from $4.69 billion, and operating income rose to $1.69 billion from $1.32 billion. The company describes two segments, Sleep and Breathing Health and Residential Care Software. Its 10-Q for the quarter ended March 31, 2026 references ongoing international sales operations and manufacturing in Australia and Singapore. The May 2025 acquisition of VirtuOx, a software-enabled provider of in-home diagnostic testing, extends the company's end-to-end sleep and breathing offerings, though the company states the acquisition is not material to its financial results.

Hidden risk.The most easily missed tension is in the hedging and obligations disclosures. The notional value of outstanding cross-currency swaps rose to $3,430.5 million at March 31, 2026 from $1,128.3 million at June 30, 2025, roughly three times the June 2025 level in nine months. These derivatives hedge foreign-currency exposure tied to Australian and Singapore manufacturing and international operations. Purchase obligations total $1.03 billion, with $984.0 million due in the period ending March 31, 2027. Total liabilities also rose to $2.21 billion from $2.01 billion. The risk-factor excerpt in the file is largely a table of contents, so readers may want to look at the full Item 1A discussion of currency, tariffs and supply chain.